rineterkib   Click here for help

GtoPdb Ligand ID: 11200

Synonyms: ERK-IN-1 | example 184 [WO2015066188A1] | LTT-462 | LTT462
Compound class: Synthetic organic
Comment: The chemical structure that was submitted to the WHO for INN rineterkib (LTT462), is claimed as example 184 in Novartis' kinase inhibitor patent WO2015066188A1 [1]. This structure maps to PubChem CID: 118045847 which provides an indication that it is an ERK inhibitor.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 4
Rotatable bonds 8
Topological polar surface area 113.16
Molecular weight 577.13
XLogP 4.12
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CNC[C@H](c1cc(F)cc(c1)Br)NC(=O)c1ccc(cc1F)c1nc(cnc1N)[C@H]1CC[C@@H]([C@H](C1)F)O
Isomeric SMILES CNC[C@H](c1cc(F)cc(c1)Br)NC(=O)c1ccc(cc1F)c1nc(cnc1N)[C@H]1CC[C@@H]([C@H](C1)F)O
InChI InChI=1S/C26H27BrF3N5O2/c1-32-11-21(15-6-16(27)10-17(28)7-15)35-26(37)18-4-2-14(9-19(18)29)24-25(31)33-12-22(34-24)13-3-5-23(36)20(30)8-13/h2,4,6-7,9-10,12-13,20-21,23,32,36H,3,5,8,11H2,1H3,(H2,31,33)(H,35,37)/t13-,20-,21+,23-/m0/s1
No information available.
Summary of Clinical Use Click here for help
LTT462 has been advanced to clinical evaluation in solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02711345 A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. Phase 1 Interventional Novartis This study was not progressed to its dose expansion phase due to the limited clinical activity of LTT462.
NCT04417621 Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma Phase 2 Interventional Novartis
NCT04294160 A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer Phase 1 Interventional Novartis